Anticancer therapeutic agents
AssigneeR.L.L. Limited
InventorsRobert J. Hickey, Linda H. Malkas
Life of this patent
Estimating the term…
Abstract
The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy.
Claims5
A method of reducing cellular proliferation of breast cancer, pancreatic cancer, or neuroblastoma cancer cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) in a patient in need thereof, comprising administering a therapeutically effective amount of a compound of the formula
- or a pharmaceutically acceptable salt thereof.
A method for reducing cellular proliferation of breast cancer, pancreatic cancer, or neuroblastoma cancer cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) comprising administering a therapeutically effective amount of a compound of the formula
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound of the formula
- or a pharmaceutically acceptable salt thereof, and further comprising one or more carriers, diluents, or excipients.
Dependencies are inferred from the claim text.